Prothena is a biotechnology company focused on the discovery and development of antibodies for the treatment of diseases that involve protein misfolding or cell adhesion. Co.'s research and development pipeline includes: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 for the treatment of Parkinson's disease; and PRX003 for the treatment of inflammatory disease and metastatic cancers. Co.'s pipeline also includes: tau antibodies for treatment of Alzheimer's disease and antibodies for the treatment of type two diabetes. Co. is also generating additional antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro.
PRTA — Key Stats (updated Monday, March 3, 11:34 AM)
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.